Myeloproliferative disorder therapy: assessment and management of adverse events--a dermatologist's perspective.
Development of cutaneous manifestations in patients with myeloproliferative disorders can be either due to the course of the disease itself or induced by some of the treatments given. The cutaneous manifestations may reveal an unknown haemopathy and/or indicate a poor prognosis. Some of these alter quality of life. Hydroxyurea has been shown to induce a variety of cutaneous adverse reactions ranging from benign effects such as hyperpigmentation to more severe leg ulcers and squamous cell carcinomas. Herein, we discuss the importance of undertaking regular physical examinations in order to identify and treat cutaneous manifestations early in their course.
Soutou
Boutros
B
Hôpital Tenon and Univ Paris 6, Paris, France.
Aractingi
Sélim
S
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003880:Dermatology / Q000379:methods*; D019468:Disease Management; D006801:Humans; D009196:Myeloproliferative Disorders / Q000150:complications* / Q000188:drug therapy; D018570:Risk Assessment; D012871:Skin Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy
D000970:Antineoplastic Agents